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Abstract 
Background: Type 2 Diabetes Mellitus (T2DM) is a well-known comorbidity to COVID-19 and coagulopathies are a 
common accompaniment to both T2DM and COVID-19. In addition, patients with COVID-19 are known to develop 
micro-clots within the lungs. The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 
virus in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological test that indicated 
clotting severity and the extent of clotting pathologies in the individual who was infected or not would be highly 
desirable.
Methods: Platelet poor plasma (PPP) was collected and frozen. On the day of analysis, PPP samples were thawed 
and analysed. We show here that microclots can be detected in the native plasma of twenty COVID-19, as well as ten 
T2DM patients, without the addition of any clotting agent, and in particular that such clots are amyloid in nature as 
judged by a standard fluorogenic stain. Results were compared to ten healthy age-matched individuals.
Results: In COVID-19 plasma these microclots are significantly increased when compared to the levels in T2DM.
Conclusions: This fluorogenic test may provide a rapid and convenient test with 100% sensitivity (P < 0.0001) and is 
consistent with the recognition that the early detection and prevention of such clotting can have an important role in 
therapy.
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Background
The standard method for detecting infection with SARS-
CoV-2 leading to COVID-19 disease involves a genotypic 
(PCR) test for the virus on nasopharyngeal swabs, but 
it is unpleasant, requires specific training, and can have 
poor sensitivity [1–7]. What would be desirable is a rapid 
and phenotypic test on the host that indicates the pres-
ence, and if possible the severity, of clotting pathologies, 
which is one of the consequences of infection. Presently, 
the standard method for this is based on CT chest scans 
for pneumonia, which have high sensitivity but lower 
specificity (see [7–10] and below), but this is neither 
cheap nor universally available.
A poor prognosis for recovery, is linked to vari-
ous comorbidities, of which Type 2 Diabetes Mellitus 
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(T2DM) is probably the most frequently mentioned 
comorbidity. It is widely recognised [11–21] that exten-
sive blood clotting has a major role in the pathophysiol-
ogy of COVID-19 disease severity and progression, yet 
so can excessive bleeding [22, 23]. The solution to this 
apparent paradox lies in the recognition [24] that these 
phases are separated in time: the later bleeding is medi-
ated by the earlier clotting-induced depletion of fibrino-
gen and of von Willebrand factor (VWF). This first phase 
of hypercoagulability is accompanied by partial fibrinoly-
sis of the formed clots, and an extent of D-dimer forma-
tion that is predictive of clinical outcomes [25]. These 
features, together with the accompanying decrease in 
platelets (thrombocytopaenia), leads to the subsequent 
bleeding. Thus it is suggested that the application of 
suitably monitored levels of anti-clotting agents in the 
earlier phase provides for a much better outcome [13, 
24]. In addition, dysregulated hemostasis in COVID-
19-associated disseminated intravascular coagulation is 
exacerbated by an inhibition of fibrinolysis, indicating 
the plasminogen-plasmin-system as a potential target to 
prevent thromboembolic complications in COVID-19 
patients [26]. In addition, patients with COVID-19-asso-
ciated respiratory failure admitted to the intensive care 
unit exhibit a hypercoagulable state which is not appre-
ciable on conventional tests of coagulation. Supranormal 
clot firmness, minimal fibrinolysis, and hyperfibrinoge-
naemia are key findings [27].
As well as the extent of clotting, including states simi-
lar to the life-threatening disseminated intravascular 
coagulation (DIC) [15], a second issue pertains to its 
nature. Some years ago, we discovered that in the pres-
ence of microbial cell wall components [28, 29], and in 
a variety of chronic, inflammatory diseases [30–32] 
(including sepsis [33]), blood fibrinogen can clot into an 
anomalous, amyloid form [34]. These forms are easily 
detected by a fluorogenic stain such as thioflavin T, or the 
so-called Amytracker stains [35]. In all cases, however, 
these experiments were performed in vitro using relevant 
plasma, with clotting being induced by the addition of 
thrombin. In our preliminary experiments this was also 
the case for plasma from COVID-19 patients, but the 
signals were so massive that they were essentially off the 
scale. However, as we report here, the plasma of COVID-
19 patients carries a massive load of preformed amyloid 
clots (with no thrombin being added), and this therefore 
provides a rapid and convenient test for COVID-19. As 
the presence of T2DM is a well-known co-morbidity, that 
significantly decreases survival and a positive outcome 




Ethical approval for blood collection and analysis of 
the patients with COVID-19, T2DM and healthy indi-
viduals, was given by the Health Research Ethics Com-
mittee (HREC) of Stellenbosch University (reference 
number: 9521). This laboratory study was carried out in 
strict adherence to the International Declaration of Hel-
sinki, South African Guidelines for Good Clinical Prac-
tice and the South African Medical Research Council 
(SAMRC), Ethical Guidelines for research. Oral consent 
was obtained from COVID-19 patients to participate in 
the study. Written consent was obtained from T2DM 
patients and healthy participants.
Patient sample
Covid‑19 patients
20 COVID-19-positive samples (11 males and 9 females) 
were obtained and blood samples collected before treat-
ment was embarked upon. Blood samples were collected 
by JS. Platelet poor plasma (PPP) prepared and stored at 
− 80 °C, until fluorescent microscopy analysis.
Type 2 Diabetes Mellitus (T2DM)
Stored Platelet poor plasma samples were randomly 
selected from our Laboratory’s stored sample repository. 
10 age-matched T2DM (6 Males and 4 females), collected 
in 2018, were used in this analysis.
Healthy samples
Our healthy sample was 10 age-matched controls (4 
males and 6 females), previously collected and stored 
in our plasma repository. They were non-smokers, with 
CRP levels within healthy ranges, and not on any anti-
inflammatory medication.
Lung CT scans
Amongst the COVID-19 patient sample 10 patients were 
admitted, but stabilized and blood drawn and sent home 
for observation. Where patients were clinically deemed 
as moderate or severely ill, CT scans of the patients 
were performed to determine the severity of the lung 
pathology. We divided our sample into mild disease (no 
CT scan) and moderate to severely ill. The CT scan and 
severity score [36] confirmed moderate to severely ill 
patients according to the ‘ground glass’ opacities in the 
lungs.
Fluorescent Microscopy of patient whole blood 
and platelet poor plasma (PPP)
A simple fluorescence assay was developed by compar-
ing fluorescent (anomalous) amyloid signals present in 
PPP from COVID-19 patients, T2DM and those from 
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healthy age-matched individuals, all of whom were 
studied using PPP that had been stored at −80 °C. On 
the day of analysis, PPP was thawed and incubated with 
the dye thioflavin T (ThT; 5  µM final concentration), 
which detects amyloid-like structures [37]. Following 
this, the sample was incubated for 30  min (protected 
from light) at room temperature. PPP smears were 
then created by transferring a small volume (5  µl) of 
the stained PPP sample to a microscope slide (simi-
lar methods were followed to create a blood smear). 
A cover slip was placed over the prepared smear and 
viewed using a Zeiss AxioObserver 7 fluorescent 
microscope with a Plan-Apochromat 63x/1.4 Oil DIC 
M27 objective.
For ThT quantification, the excitation was set at 450 
to 488 nm and emission at 499 to 529 nm. Unstained 
samples were also prepared with both healthy and 
COVID-19 PPP, to assess any autofluorescence. Micro-
graph analysis was done using ImageJ (version 2.0.0-rc-
34/1.5a). The % area of amyloid were calculated using 
the thresholding method. This method allows a meas-
urement of area of amyloid signal. The RGB images are 
opened in ImageJ, each image is calibrated by setting 
the scale (calculated using the image pixel size and the 
known size of the scale bar). Each image is then con-
verted to black and white (8 bit, this is adjusted under 
the image type setting). The next step is to threshold the 
image by adjusting the background intensity to white 
(255) and then thresholding the now black amyloid sig-
nal (in these images between 11 and 15). We used the 
Huang setting during thresholding. Huang’s method is 
an optimization method which finds the optimal thresh-
old value by minimizing the measures of fuzziness. 
The black amyloid area is then analyzed using the ana-
lyze particle setting where we use the particle size that 
is measured from 1 to infinity. The particle size setting 
allows us to exclude any background signal that might 
not be true amyloid signal. The area per data per particle 
size that is generated is then copied into a spreadsheet 
(see our raw data). Statistical analysis was done using 
GraphPad Prism 8 (version 8.4.3). Sensitivity and speci-
ficity of the data were calculated according to the follow-
ing calculations:
Sensitivity = true positive fraction
=
true positive× 100%
true positive + false negatives
Specificity = true negative fraction
=
true negatives× 100%
true negatives + false positives
Results
Age-matched COVID-19 (average age 49.9y) and 
healthy individuals (58.8y), and T2DM (62.1y) were 
used in this analysis (p = 0.06). Platelet poor plasma 
(PPP) was collected and frozen. On the day of analy-
sis, all PPP samples were thawed and analysed. We also 
confirmed that the same results are visible in freshly 
prepared PPP samples. Figure  1 shows representative 
CT scans of four of the COVID-19 patients. Raw data 
are shared in https ://1drv.ms/u/s!AgoCO mY3bk KHirZ 
Ou5YK Plq1x 5f1AQ ?e=xmWGK m.
Figures  2, 3, 4, 5 show representative fluorescence 
micrographs of PPP from healthy, T2DM and COVID-
19 individuals. In healthy PPP smears (Fig.  2), very lit-
tle ThT fluorescent signal is visible. In plasma smears 
from T2DM (Fig. 3), individuals, there were a significant 
increase in signal, compared to controls, and an even 
more pronounced increase in signal in COVID-19 indi-
viduals (Fig. 4), where abundant amyloid signal is noted. 
Note that these signals were as received; no thrombin was 
added to induce clotting. Figure  5 shows the additional 
presence of fibrous or cellular deposits in the PPP smears 
of COVID-19 patients. There have been reports of exten-
sive endotheliopathy in COVID-19 patients [38, 39], and 
these deposits might contribute to this endotheliopathy. 
Figure 6a and b show box plots of the % area of amyloid 
signal calculated from representative micrographs of 
each individual. A nonparametric one-way ANOVA test 
(Kruskal–Wallis test) between all groups showed a highly 
significant difference (p =  < 0.0001). However, a Mann–
Whitney analysis between the mild and the moderate 
to severe COVID-19 individuals showed no significant 
Fig. 1  a–d Representative CT scans of a COVID-19 patient. Yellow 
arrows show ground glass opacities
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difference (p = 0.554). Amyloid formation in plasma is 
therefore present in the early stages of COVID-19, when 
the patients are sufficiently unwell to visit the hospital 
and in need of stabilization.
Fig. 2  a–d Representative fluorescence micrographs of platelet 
poor plasma from healthy individuals. Most signals are very weak, as 
shown by the arrows in a 
Fig. 3  a–f Representative fluorescence micrographs of platelet poor 
plasma from Type 2 Diabetes Mellitus (T2DM) patients
Fig. 4  a–h Representative fluorescence micrographs of platelet poor 
plasma from COVID-19 patients
Fig. 5 Fibrous or cellular deposits in the plasma smears from 
COVID-19 patients
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Sensitivity and specificity
Table 1 shows the average % amyloid area for each sam-
ple, ranked from lowest to highest values, as well as the 
sensitivity and specificity calculations. We set the cut-
off % amyloid area as 1.3% for controls, and 3.05% for 
T2DM (see Table 1 and raw data file in shared data link). 
Using these calculations, the % amyloid area sensitiv-
ity and specificity in control versus COVID-19 samples 
is 85% and 100% respectively, and % amyloid sensitivity 
and specificity in T2DM versus COVID-19 is 69% and 
67%, respectively. Similarly, the % amyloid area sensitiv-
ity and specificity for controls versus T2DM is 100% and 
100% respectively, suggesting that T2DM is potentially 
a big confounder. These results suggest that T2DM dis-
ease increase the propensity for an individual to develop 
COVID-19.
Discussion
Strongly bound up with the coagulopathies accompany-
ing severe COVID-19 disease is the presence of hyperfer-
ritinaemia (in cases such as the present it is a cell damage 
marker [40]) and a cytokine storm, [41–45] which usually 
occurs in the later phase of the disease [24]. In addition, 
there has been reports of pulmonary vascular endotheli-
alitis, thrombosis, and angiogenesis in Covid-19 [39]. In 
addition, excess iron has long been known to cause blood 
to clot into an anomalous form [46], later shown to be 
amyloid in nature [28–34]. Increased serum ferritin lev-
els are also known to be present in T2DM [47–50]. These 
kinds of phenomena seem to accompany essentially every 
kind of inflammatory disease (e.g. [51]), but the amyloi-
dogenic coagulopathies are normally assessed following 
the ex vivo addition of thrombin to samples of plasma.
Many clinical features of COVID-19 are unprece-
dented, and here we demonstrate yet another: the pres-
ence in PPP to which thrombin has not been added 
of amyloid microclots. These microclots are also an 
pathological feature of PPP from T2DM patients, how-
ever there is a significant increase of the microclots in 
COVID-19 patients. This kind of phenomenon explains 
at once the extensive microclotting that is such a feature 
of COVID-19 [11], and adds strongly to the view that its 
prevention via anti-clotting agents should lie at the heart 
of therapy. In addition, individuals with T2DM are more 
prone to develop microclots, due to an increased pres-
ence of circulating inflammatory biomarkers that cause 
hypercoagulability. T2DM patients are therefore pre-
disposed due to their condition. When these individu-
als then contract SARS-CoV-2, they are already prone to 
hypercoagulation. This hyperocuagulable predisposition, 
explains why individuals with T2DM are more prone to 
develop severe hypercoagulability when diagnosed with 
COVID-19. Although fluorescence microscopy is a spe-
cialized laboratory technique,  TEG® is a well-known 
point of care technique, which is cheap and reliable. Sam-
ples can be collected and PPP can be analysed immedi-
ately, or frozen and thawed for later analysis. All told, the 
relative ease of fluorescence microscopy, speed (40  min 
including 30  min ThT incubation time) and cheapness 
of the assay we describe might be of significant utility 
in differentiating COVID-19 from other inflammatory 
diseases.
Of course this must also be monitored (e.g. via Throm-
boelastography [52–55]) lest the disease enters its later 
phase in which bleeding rather than clotting is the 
Fig. 6  a, b Amyloid % area in platelet poor plasma smears with 
mean and SEM (p =  < 0.0001). a All controls, Type 2 Diabetes Mellitus 
(T2DM) and all COVID-19 patients. b All controls vs T2DM vs 10 mild 
and 10 moderate to severely ill COVID-19 patients
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greater danger [24]. Although not shown here, an impor-
tant consideration is that  TEG® can be used to study the 
clotting parameters of both whole blood and PPP. Whole 
blood  TEG® gives information on the clotting potential 
affected by the presence of both platelets and fibrinogen, 
while PPP  TEG® only presents evidence of the clotting 
potential of the plasma proteins [52–55].
Point-of-care devices and diagnostics like  TEG® 
are also particularly useful to assess fibrinolysis. In 
COVID-19 patients, Wright and co-workers reported 
Table 1 Sensitivity and specificity of % area amyloid (% amyloid was scaled for each sample type from low to high)
Controls T2DM COVID-19 Controls vs COVID-19
0.09% T2DM Cut-off % amyloid area set 
as 3.05%
True positives 17 × COVID-19
0.11% True negatives 10 × Controls
0.18% False positives 0
0.24% False negatives 3 × COVID-19
0.36% Sensitivity 85%
0.37% Specificity 100%
0.43% T2DM vs COVID-19
0.48% True positives 9 × COVID-19
0.80% True negatives 10 × T2DM
0.81% False positives 5 × T2DM
0.96% 1.07% False negatives 4 × COVID-19
1.23% Sensitivity 69%




1.86% True positives 10 × T2DM
2.12% True negatives 10 × Controls
2.73% False positives 0
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fibrinolysis shutdown, confirmed by complete failure of 
clot lysis at 30 min on the  TEG® [56]. Thus  TEG® can 
therefore predict thromboembolic events in patients 
with COVID-19 [56].
Conclusion
What we have shown here is that the clotting that is 
commonly seen in COVID-19 patients is in an amy-
loid form that forms large deposits that might be able 
to occlude fine capillaries. In addition, these depos-
its would interfere with fibrinolysis and cause the 
decreased ability to pass  O2 into the blood that is such a 
feature of the disease. As T2DM is a significant comor-
bidity to COVID-19, exceptional care must be taken 
when such patients are diagnosed with COVID-19. 
Consequently, the prevention of coagulopathies must 
lie at the heart of successful therapies.
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